Neogen Chemicals Reports Q1 FY27 Net Profit Surge of 66.8% YoY to ₹17.11 Crore; Operational Revenue Up 34% at ₹250.29 Crore
Neogen Chemicals reported unaudited consolidated Q1 FY27 results for the quarter ended June 30, 2026. Revenue from operations rose 34.04% YoY to ₹250.29 crore. Net profit increased 66.76% YoY to ₹17.11 crore, with operating margin at 19.35%. The company said net worth rose to ₹984.47 crore and debt equity improved to 1.40x. Shares last traded on BSE near ₹2,063.
How this was made
The 30-second read
Why it matters
The release contains a full earnings snapshot: revenue growth, profit growth, operating margin expansion, and improved balance-sheet leverage ratios, which together can change near-term expectations for profitability and risk.
Market read
Traders can use the reported earnings and margin expansion plus improved leverage to reassess near-term valuation and risk for NEOG.
What to watch
Other income rose sharply (₹3.86 crore vs ₹1.18 crore YoY), and the article does not break down whether margin gains are driven by pricing, mix, or one-off items.
Background
Neogen Chemicals disclosed unaudited consolidated Q1 FY27 results for the quarter ended June 30, 2026.
Ticker impact
Neogen Chemicals reported Q1 FY27 revenue from operations of ₹250.29 crore (+34% YoY) and PAT of ₹17.11 crore (+66.8% YoY).
Likely positive bias for the stock on earnings momentum, though magnitude depends on how these results compare to Street estimates not provided here.
The article provides multiple concrete datapoints: revenue +34% YoY, PAT +66.76% YoY, operating margin 19.35% (up from 17.82%), and improved debt ratios (debt equity 1.40 vs 1.63). These are typically supportive for valuation and sentiment, but the absence of consensus/forward guidance limits precision.
Market effects
Strong specialty chemicals earnings with margin expansion can support sentiment for Indian specialty chemicals peers, but no peer-specific read-across is provided.
May influence broader India small/mid-cap sentiment given the reported profitability and leverage improvement.
Limited direct global impact because the disclosure is company-specific and in INR, with no international guidance or macro linkage stated.
Counterpoint
Finance costs were still sizable (₹20.81 crore) and inventory turns worsened (226 days vs 201), so the earnings quality and sustainability of margin expansion could be questioned.
Key entities
- companyNeogen Chemicals Limited
Reported Q1 FY27 unaudited consolidated financial results with strong YoY growth in revenue and net profit.
